chartexchange

Defence Therapeutics Announces Convertible Debenture Interest Payment

Newsfile | Oct 23, 2026 4:15 PM EDT

Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce convertible debentures interest payment in common shares of the Company. The Company announces that, in accordance with the terms and conditions of convertible debentures...

Read original article